Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 3.95e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 3.82e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 1.03e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 4.87e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-4 | 3.71e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-5 | 4.16e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 4.22e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 1.75e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.51e-3 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 1.51e-3 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 5.00e-2 | 2.68e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 1.07e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 5.00e-2 | 4.66e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 4.35e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 2.57e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 3.21e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 2.29e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 5.55e-3 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 1.67e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.35e-2 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 9.42e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.37e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.44e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 2.06e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 4.99e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 4.72e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 1.05e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 2.04e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 1.23e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 1.23e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.18e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.00e-4 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 2.51e-3 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 3.68e-3 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 2.23e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 3.50e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-3 | 4.05e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-4 | 4.89e-2 |
Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 7.09e-3 |
Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.28e-2 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-4 | 4.78e-2 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-3 | 2.51e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 3.26e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 1.45e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 1.72e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 3.44e-2 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 5.00e-2 | 2.01e-2 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 1.00e-2 | 1.03e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-3 | 2.21e-2 |
Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.55e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 4.35e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 2.19e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-4 | 4.35e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 5.78e-4 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 2.28e-2 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 2.29e-2 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-4 | 9.42e-3 |
Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 5.00e-2 | 1.26e-2 |
Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.81e-2 |
Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 2.90e-3 |
Pubertal Anthropometrics | Late Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 4.98e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 2.87e-3 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-2 | 6.53e-3 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 7.91e-3 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 4.11e-2 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 7.10e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 3.17e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 3.90e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 3.01e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 4.89e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.49e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.75e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 4.59e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 3.40e-2 |
Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 4.83e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 6.98e-3 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 9.22e-3 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-5 | 1.76e-2 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.10e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 2.77e-2 |
Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-4 | 1.52e-2 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 1.77e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 2.41e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 7.17e-3 |
Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-2 | 4.96e-2 |
Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.40e-2 |
Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 1.00e-2 | 1.17e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.69e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 1.85e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 4.87e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 6.70e-3 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 5.85e-3 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 1.83e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 3.49e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-5 | 1.40e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 4.88e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.45e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.64e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.51e-2 |
Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 4.32e-2 |
Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-2 | 3.78e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 3.13e-4 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 9.93e-5 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 1.66e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 1.34e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-3 | 4.59e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-4 | 1.66e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-5 | 1.37e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 1.00e-2 | 1.65e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 1.00e-3 | 2.28e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.